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Abstract:
Aim: To assess the efficacy of scaffold mediated localized chemotherapy in cancer.
Materials and Methods: PubMed, Cochrane Library, and SCOPUS databses were searched
for articles reporting the use of scaffold mediated localized drug delivery in cancer. Essential
data including scaffold fabrication material and methods, the drug dosage and release
duration, its effect on the cancer cells were extracted.
Results: 15 articles out of 60 screened, fulfilled the eligibility criteria. Among the 15 studies, 5
studies included only cell lines and 2 studies were only on mouse models while 8 studies
involved a combination of cell lines and mouse models. The scaffold materials ranged from
synthetic polymers such as poly-lactide, polycaprolactone, etc to natural scaffolds including dperiosteum, human micro-fragmented adipose tissue, etc.
Conclusion: Studies differed with respect to a wide number of variables ranging from the type
of scaffold material used, the fabrication procedure, the nature of the drug used, and the tools
used to assess the effect of the scaffold mediated drug on cancer. Due to these variables, it
was not possible to make any direct comparison of the efficacy of therapeutic strategy used in
each of these studies. Irrespective of the differences, a common consensus in all the included
studies was that scaffold mediated localized drug delivery effectively reduced the cancer cell
viability by increasing the bioavailability of the drug to the target tissue, while its localized effect
reduces the risk of systemic toxicity.
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Conclusion:
Irrespective of the drugs, scaffold materials and assessment tools used, scaffold mediated
localized delivery of chemotherapeutics is a potentially exciting method for drug delivery to
solid tumours with the aim of preventing or minimising adverse systemic toxicity. However,
scaffold placement and other variables discussed in this paper mean that the introduction of
this potential method of chemotherapy is dependent on further research and appropriately
designed, prospective clinical trials
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Scaffold: Bacterial (natural) Cellulose-Alginate (BC-Alg)
Drug: Doxorubicin (Dox)
Cell Lines: H29 Human colorectal adenocarcinoma

Scaffold: D – periosteum (natural)
Drug: Adriamycin (ADM)
Cell Lines: Human Osteosarcoma Cells (HOSs)

Study groups
Mouse with SCC-9 cancer was divided into 4 groups:
Group 1: no treatment
Group 2: implanted scaffolds without diclofenac
Group 3: implanted scaffolds loaded with diclofenac
Group 4: diclofenac was given orally
Group 1: Soluble free drug in µM (100,150,200)
Group 2: Scaffold without drug
Group 3: Scaffold with drug 9.55±1.87µmol/gm
Group 4: Scaffolds with drug 42.25±3.15 µmol/gm
Group 1: Control group (medium alone)
Group 2: adriamycin free drug
Group 3: adriamycin gelatin microspheres (ADM‐GMS)
Group 4: ADM-GMS D‐periosteum
Group 5: adriamycin poly (dl‐lactide‐coglycolide) gelatin
microspheres (ADM‐PLGA‐GMS)
Group 6: ADM‐PLGA‐GMS- D‐periosteum
Group 7: GMS-D Periosteum

Scaffold: Poly(caprolactone)–poly(ethylene glycol)
(PCL/PEG) (Electrospinning)
Drug: 17-dimethylaminoethylamino-17-demethoxy
geldanamycin (17-DMAG)/ Cell Lines: A549 lung cancer
cells

Group 1: untreated cells
Group 2: Cells treated with free drug
Group 3: Cells treated with blank scaffolds
Group 4: Cells treated with drug-loaded scaffolds

In vitro cell lines and invivo mouse model

Scaffold: Acetalated dextran (Ace-DEX), polyester,
poly(L-lactide) (PLA) Dissolution
Drug: doxorubicin (DXR)
Cell Lines: Human glioma cell lines U87-MG, LN-18, and
LN-229

Group 1: No treatment
Group 2: Ace-DEX blank
Group 3: Ace
DEX/10DXR
Group 4: PLA/blank
Group 5: PLA/10DXR

In vitro cell lines and in
vivo female mice model

Scaffold: poly (L-lactide) (PLLA) fibrous scaffolds blent
Electrospinning
with the mesoporous silica nanoparticles (MSNs)
Drug: doxorubicin (DOX)
Cell Lines: MDA-MB-231

Group 1: untreated
Group 2: P-F (Blank)
Group 3: P-D-F
Group 4: P-M/D-F
Group 5: P-M/D-S-F (with sodium bicarbonate)

In vitro Cell Lines

Workflow
6.

Scaffold material/Drug incorporated/Cancer type
studies

Group 1: control group
Group 2: Unloaded film, Group 3: DTX-loaded film
In-vitro cell lines and in- Scaffold: poly-D,L-lactide (PDLLA) Electrospinning
Group 4: Local subcutaneous injection of DTX 15mg/kg
vivo mice model study
Drug: docetaxel(DTX)/4T1 Cell Lines: breast cancer cells
Group 5: Intraperitoneal injection of DTX

In vitro cell lines

In vitro cell lines and in
vivo nude rats

In vitro cell lines and invivo mouse model

In vitro cell lines and Invivo mice model

In vitro cell lines and In
vivo female mice

Scaffold: cyclodextrin polymer (polyCD) functionalized
hydroxyapatite (HA) admixing and sublimation
Drug: Gentamicin and cisplatin
Cell Lines: MG63 osteosarcoma cell lines

Scaffold: Silk Fibroin(SF)- chitosan(CS) lyophilization
Drug: Emodin
Cell Lines: Breast cancer cell line GILM2
Scaffold: poly(glycerol stearic acid-co-ecaprolactone)PGC-C18/10, poly(glycerol-co-ecaprolactone)PGC-OH adhered to collagen scaffolds
(solution, evaporation and adhering)
Drug: hydroxycamptothecin HPCT
Cell Lines: Lewis lung carcinoma cells
Scaffold: human micro-fragmented adipose tissue
(MFAT)
Drug: Paclitaxel(PTX)
Cell Lines: human Pancreatic Adenocarcinoma cell line,
human Glioblastoma cell line U87MG and human, wild
type and luciferase (Luc) transfected Neuroblastoma
(NB) (IMR-32, SHSY5Y, HTLA-230, NB1691) cell lines/
orthotopic animal model of Neuroblastoma (NB)

Group 1: polyCD-HA/cis
Group 2: polyCD-HA/dual
Group 3: polyCDHA/genta
Group 4: polyCD-HA
Group 5: HA granules

Drug release duration: 7 weeks
Drug dosage released: 219.8±18.5 (in-vivo); 234.6±17.7 (in-vitro)/or
77.5% (in vivo); 82.7% (in vitro)

7-week survival rate: Group 1- 25%; Group 2- 10%; Group 3- 89%; Group 4- 10%
Group 3 recurrence tumor weight was * lower than other groups
Ki-67 immunostaining was * lower in group 3 than other groups
Caspase 3 immunostaining was the same in all groups

Group 3 showed * greater survival rate and tumor inhibition than other groups/
The limitation was that the in vitro drug release was higher than in-vivo which in
turn could have reduced the inhibitory effect on the cancer in-vivo

Cell Viability % at 24 and 48 hrs
Group 2: 103±3.1 and 97.4±2.1
Group 3: 59±7.2 and 55±8.2
Group 4: 53±1.6 and 37±0.5

Anti-cancer effect with Dox loaded into BC-Alg films was more prominent than
free drug. BC-Alg formulation, drug loading quantities and release kinetic
conditions can modulate cytotoxic effect of Dox.

Drug release duration: 48 hrs max.
Drug dosage released: Group 3: 76±5(24hr), 169±5(48hr)
Group 4: 77±5(24hr), 181.0±8(48hr)

Drug release duration: Maximum of 10 hrs
Drug dosage released: Group 2: Released within 1 hr
Group 3: Cumulative release of 80% within 10hr
Group 4: Cumulative release within 10hr approx. same as group 3
Group 5: the cumulative release of 80% in 48 hrs
Group 6: the cumulative release of 76.6% in 48 hrs

Drug release duration: 7 hrs max.
Drug dosage released: 50 – 95% drug is released from 2-6 hrs
96% of the drug was released in 7 hrs

D‐periosteum scaffold crosslinked with drug‐loaded microspheres showed high
The CCK‐8 cell counting test Group 2: more HOSs were killed in 2hr and 12hr, with the inhibition rate of 42%, which
porosity slow release of ADM inhibiting HOS cancer cells.
was higher than those in other groups
Future osteosarcoma animal model studies will be required to investigate the
At 24hr, Group 5 and 6 showed a higher rate of inhibition than other groups
potential of drug-loaded D‐periosteum against osteosarcoma and supporting
Groups 3 and 4 Vs Groups 5 and 6 showed similar cell inhibition rates, respectively at all three-time points
local bone tissue regeneration
Expression of HSP90 mRNA
Group 2: expression levels reduced to about 13, 32, and 48% after 24, 48 and 72h, respectively
Group 4: Expression levels reduced to about 39, 57, and 79% after 24, 48 and 72h, respectively

Telomerase activity
Group 2: The activity was reduced to 31, 51, and 71% after 24, 48 and 72h, respectively.
Group 4: Reduced telomerase activity of the cells to about 54, 66, and 83% after 24, 48 and 72h, respectively.
Survival rate: Ace-DEX/10DXR statistically better compared to
Drug release duration: 35 days max.
Ace-DEX/blank (p < 0.005) and ‘no treatment’
Drug dosage released: Ace-DEX/10DXR and PLA/10DXR released
PLA/10DXR statistically better
compared to ‘no treatment’ control group (p < 0.05), but was not significant compared to
similar amounts of DXR (approximately 50%) over 35 days
PLA/blank
Progression-free survival rates: Ace-DEX/10DXR statistically better compared to Ace-DEX/blank (p < 0.01) and ‘no
Steady-state release from Ace-DEX scaffolds is faster than that from
treatment’
PLA, which releases the
majority of the DXR within the first 24 hours
PLA/10DXR statistically better
compared to ‘no treatment’
In-vitro anti-tumor activity:
Drug release duration: 100 days
P-M/D-S-F group had the strongest inhibition on tumor cells
Residual tumor tissues: Necrosis of P-M/D-S-F was very remarkable
Drug dosage released: Lower initial burst and longer release time of Pamong all the groups
M/D-F and
Expression of Bcl-2 and Bax:
P-M/D-S-F compared with P-D-F at neutral pH
P-M/D-S-F showed higher levels of Bax and lower levels of Bcl-2 compared to all other groups
Expression of TNF-α and caspase-3: P-M/D-S-F showed highest levels of TNF-α and caspase-3
Cytotoxicity against 4T1:
Drug release duration: 24 days
Group 1 and 2: No cytotoxicity
Drug dosage released: Approximately 23.3%, 25.3% and 29.6% of DTX
Group 3,4 and 5: cell growth inhibition rates of 20%, 34%, and 54%, respectively
was released in 24 days from the 5, 10 and 20 wt% DTX/PDLLA
Locoregional recurrence: Locally administrated DTX/PLA reduced locoregional recurrence after resection of the
scaffolds, respectively
primary tumor
Overall survival was improved in the DTX/PDLLA group compared with all the other groups

17-DMAG-loaded PCL/PEG nanoﬁbers had more inhibitory eﬀect on cell
proliferation, HSP90 mRNA expression, and telomerase activity than free 17DMAG.
Drug-loaded scaﬀolds can be used for local drug administration and prevention of
post-surgical local lung cancer recurrence.

Both PLA/10DXR and DXR loaded scaffolds showed sustained release of DXR over
same period of time.
Higher and sustained amount of DXR release from Ace-DEX scaffolds led to higher
suppression of tumor recurrence and complete remission in 43% of mice.

P-M/D-S-F can kill the post-surgical residual cancer cells as evidenced by reduced
expression of Bcl-2 and TNF-α and a increased expression of Bax and caspase-3.

Electrospun DTX-loaded PDLLA nanofibers provide prolonged and sufficient
cytotoxic drug locally, preventing local tumor recurrence post-surgically

Biodegradable polyCD functionalized HA material can load higher amounts of one
or two selected drugs (antimitotic, antibiotic, etc.) which can be gradually
released into tumor surroundings maintaining the therapeutic efficacy of drug

Group 1: SF only
Group 2: SF-CS blank scaffolds
Group 3: emodin-loaded SFCS scaffold

Drug release duration: 24 days
Drug dosage released: SF scaffolds showed highest emodin release as
compared to all SFCS blends However, there was no difference in
release between various blends of different concentrations of SF and
CS.

Cell Viability: SFCS scaffolds signiﬁcantly decreased the number of viable cells as compared to cells in culture dishes
(no SFCS, no emodin, p<0.01) and cells exposed to SFCS scaffolds only
In vivo response: emodin-loaded SFCS scaﬀold group showed decreased tumor presence and size
Cell Density: The cell density in remodeled SFCS scaffold (3238 ± 152 cells/mm2) was signiﬁcantly higher (p<0.05)
than the emodin loaded SFCS scaffold (2733 ± 118 cells/mm2).

Liposomal emodin-loaded 25:75 SFCS scaﬀold composites provide good
mechanical integrity, optimal drug loading and release over time, and reduced
breast cancer cell viability in vitro. Scaffolds were effective in reducing tumor
presence, scaffold degradation and increasing remodelling and new tissue
deposition in vivo.

Group 1: PGC-OH unloaded
Group 2: HCPT loaded PGC-OH
Group 3: Unloaded PGC-C18
Group 4: HCPT loaded PGC-C18

Cytotoxic Studies (in-vitro): HCPT loaded PGC-C18 films exhibited significant cytotoxicity for 7 weeks compared to
Drug release duration: 7 weeks/ 3 weeks
unloaded PGC-C18
Drug dosage released: PGC-C18 released in a more controlled manner
In vivo mouse studies: Local tumor growth was suppressed in loaded PGC-C18 compared with unloaded films and
than PGC-OH
intravenous HPCT

Group 1: MFAT untreated
Group 2: MFAT-PTX
Group 3: Devitalised MFAT (DMFAT) untreated
Group 4: DMFAT-PTX
Group 5: Condition medium of MFAT-PTX and DMFATPTX

Drug release duration: Total duration 60 days
Drug dosage released: after 1 day, the PTX released by DMFAT-PTX
was double (p-EC= 124.8 ±15.59 ng/ml) compared to MFAT-PTX
The concentration of PTX derived from DMFAT-PTX was always higher
than that released by MFATPTX

Ceren Kutlu/2014/Turkey In vitro cell lines

Dong Gao/2017/China

Group 1: Control
Scaffold: Purine-scaffold TLR7 agonist (GD5)
Group 2: DOX intratumoural
Group 3: GD5 intratumoural
Drug: Doxirubicin
Cell Lines: EL4 T cell lymphoma cells injected in a mouse Group 4: GD5 intraperitoneal
Group 5: Both GD5 and DOX intratumoural
model
Group 6: DOX intratumoural GD5 intraperitoneal

Jacob H. Swet/2013/North
In-vivo rat model
Carolina

Inference/Potential limitations

Cell Vitality against osteosarcoma cells: No difference (p>0.05) between polyCD-HA/dual and polyCD-HA/cis, both
showed strong cytotoxic effect (20%±3%) to MG63 cells
HA, polyCD-HA and polyCD-HA/genta showed no toxic effect to MG63 cells with a similar level of cell vitality
(95%±4%) to control group

Group 1: Drug-eluting scaffold
Group 2: Non-eluting scaffold
Scaffold: PGA-TMC and porcine gelatin (electrospinning)
Group 3: Non-eluting scaffold/phosphate-buffered
Drug: Flofirinox
solution group in which the cell medium was
Cell Lines: Pancreatic Cancer cells
supplemented with phosphate-buffered solution as a
control

Scaffold: Silica-calcium-phosphate nanocomposite
(SCPC75) (solution and dried)
Drug: Cisplatin
Cell Lines: A rat model of Hepatocellular Carcinoma
(HCC)

Effect of the scaffold mediated drug on the cancer

Drug release duration: 48 hrs
Drug dosage released: in different media:
84, 82, and 74% respectively for Cis loaded scaffolds in human blood
plasma, in 10% FBS enriched MEM and serum-free MEM

Scaffold: poly-lactic-co-glycolic acid (PLGA)-chitosan
(emulsion–diffusion–evaporation)
Drug: 5-fluorouracil (5-FU) and bevacizumab
Cell Lines: Human Glioblastoma cell line T98G and
Human Umbilical vein Endothelial Cells (HUVECs)

In vivo mice

Scaffold mediated drug release duration/dosage

Group 1: Chitosan blank scaffold
Group 2: Chitosan scaffold loaded with 5-FU-PLGA
nanoparticles
Group 3: bevacizumab loaded scaffold
Group 4: 5-FU- and bevacizumab-loaded scaffold

Group 1: Control Untreated
Group 2: Systemic Cisplatin (sCis)
Group 3: Blank SCPC75 placed adjacent to tumor (ADJSCPC75)
Group 4: Cis-SCPC75 placed adjacent to tumor (ADJSCPC75-Cis)
Group 5: Blank SCPC75 within tumor mass IT-SCPC75
Group 6: Cis-SCPC75 placed within tumor IT-SCPC75-Cis

Anti-tumor activity: MFAT-PTX, DMFAT-PTX and condition media derived from both resulted in more than 90% of
CFPAC-1 growth inhibition. Anticancer activity was also effective against IMR-32 and U87MG, (NB) and (GBM) cell
Both MFAT and DMFAT work as natural biological scaffolds and help in efficiently
lines
killing cancer cells both in vito and in vivo by absorbing releasing significant
Anti-angiogenesis: MFAT-PTX, DMFAT-PTX and condition media derived from both are cytotoxic in all concentrations
amount of PTX
against Human Umbilical Vein ECs
In vivo: local administration of DMFAT-PTX at tumor site after its surgical resection blocked or delay NB relapse

MTT: Proliferation of pancreatic cancer cells on the drug-eluting scaffolds was arrested during the 3-week period of
observation
Drug release duration: for 3 weeks
Apoptosis assay: Apoptosis of the pancreatic cancer cell populations on the drug-eluting scaffolds escalated through
Drug dosage released: The release of FOLFIRINOX from scaffold could week 3. However, no significant apoptosis was observed in cancer cell populations on either the non-eluting
scaffolds or the tissue culture plates during the 3-week study period
be attributed to the combined effect of physical disintegration and
In vivo tumor volume:
chemical decomposition/
Group 1: 302.24 ± 103.59 mm3 Group 2: 434.22 ± 132.98 mm2 Group 3: 951.78 ± 178.21 mm2
Drug release duration: 80 days Drug dosage released: Burst release
was observed in the first 24h with release of 15% of encapsulated 5FU. 5-FU has continued in a controlled manner during the following
days/

-----------

Cell Viability:
Group 1 and Group 3: No effect
Group 2 and Group 4: Antiproliferative against T98G
Anti-angiogenesis: HUVECs are viable in the presence of blank and only bevacizumab-loaded scaffold. In group 2
and 4, 5-FU prevented cell proliferation
Survival Time: Mice treated with GD5 have more survival than control or DOX treated groups.
Group 5 and 6 significantly improved survival compared with Group 3 and 4
Amongst group 5 and 6: Group 5 showed a notable increase in survival compared with group 6
Systemic antitumor effect: Either Co i.t. or Co i.p. group exhibited improved tumoricidal effectiveness compared
with single-drug treatment groups
Anti-tumor Immunity in Long-term Surviving Mice:
EL4 tumor cells were significantly more sensitive to the effector cells from the drugs administration groups than Ctrl
group; but no significant difference among GD5 i.t., GD5 i.p. and Co i.p. groups were observed. Only Co i.t. group
and supra three groups have a significant difference

Drug release duration: 14 days
Drug dosage released: In vivo SCPC75-Cis released 55% of the loaded
cisplatin.
ADJ-SCPC75-Cis or IT-SCPC75-Cis compared with control show similar
serum platinum concentration.
sCis-treated animals showed increased levels of platinum compared
with all other groups
Platinum content in tumor tissue: IT-SCPC75-Cis showed signiﬁcantly
increased intratumoral platinum greater than other treatment groups

HPCT loaded scaffolds help in controlled and sustained release of drug alongwith
complete inhibition of tumor at a dose which is three times lesser compared to
required intravenous dose

Tumor Growth: ADJ-SCPC75-Cis and IT-SCPC75-Cis demonstrated slower tumor growth compared with both control
and sCis-treated animals
Histological analysis: No detectable necrosis in untreated, control tumors. Small areas of necrotic cell death were
detected in animals receiving sCis
Signiﬁcant areas of tissue necrosis were observed in tumors receiving ADJ-SCPC75-Cis or IT-SCPC75-Cis treatment
No signiﬁcant difference was measured between the necrotic area in animals treated with ADJ-SCPC75-Cis and
ITSCPC75-Cis

The ability to destroy CD133+ and CXCR4+ cells in cancer tissue helped
FOLFIRINOX loaded scaffolds in stabilizing tumorigenesis and preventing hepatic
metastasis
Limitations: heterogeneous distribution of chemotherapeutic agents in fibers and
shorter shelf-life of the scaffold

Double effective chitosan scaffold containing anticancer and antiangiogenic agent
inhibits tumor cells, T98G glioblastomas, by releasing 5-FU, and prevents
proliferation of HUVECs, by releasing bevacizumab

Combination therapy including TLR7 agonist GD5 and conventional drugs, like
DOX can enhance antitumor effectiveness by generating strong cytokines and
increasing immune response. This will help in eradicating both local and distant
tumors enhancing local and systemic immune response

Loocal cisplatin delivery to the tumor mass using SCPC75 nano scaffold helps in
overcoming the systemic toxicity of the drug which is associated with daily
injection of cisplatin. This also increases the intratumoral drug delivery to inhibit
the tumor growth

